Colesevelam Indications
Colesevelam is FDA-approved for lowering LDL cholesterol in adults with primary hyperlipidemia, improving glycemic control in adults with type 2 diabetes, and reducing LDL-C in pediatric patients (ages 10-17) with heterozygous familial hypercholesterolemia. 1
FDA-Approved Indications
Colesevelam hydrochloride is indicated as an adjunct to diet and exercise for:
- Primary Hyperlipidemia: Reducing elevated LDL-C in adults, either as monotherapy or combined with statins 2
- Type 2 Diabetes: Improving glycemic control in adults (unique among lipid-lowering agents as the only FDA-approved drug for both LDL-C and glucose lowering) 2
- Pediatric Heterozygous Familial Hypercholesterolemia: Lowering LDL-C in boys and post-menarchal girls aged 10-17 years who cannot reach target levels despite adequate diet and lifestyle modifications 1
Efficacy Profile
- Monotherapy: Reduces LDL-C by 15-22% 2
- Combination with statins: Provides an additional 10-16% LDL-C reduction 2
- Glycemic control: Reduces HbA1c by approximately 0.5% (4 mmol/mol) in patients with type 2 diabetes 3
Critical Contraindications for Your Patient
Colesevelam is contraindicated in patients with triglycerides >500 mg/dL, history of hypertriglyceridemia-induced pancreatitis, or bowel obstruction. 1
Specific Concerns with Your Patient's Profile:
Elevated liver enzymes: While colesevelam is non-systemic and not metabolized by the liver, post-marketing reports document increased transaminases 1. The FDA label notes this as a laboratory abnormality to monitor 1. However, colesevelam may actually be safer than systemic agents in hepatic dysfunction since it acts only in the GI tract 4.
Impaired renal function: Colesevelam is non-systemic and not renally cleared, making it theoretically safe in renal impairment 4. Unlike systemic lipid-lowering agents, no dose adjustment is required for renal dysfunction 5. This is a potential advantage over statins and other systemically absorbed agents.
Hyperchloremia: This is not listed as a contraindication or precaution in the FDA label 1. Colesevelam does not directly affect electrolyte balance.
Albuminuria: Not a contraindication. The drug's non-systemic nature means it doesn't undergo renal excretion 4.
Important Warnings
- Hypertriglyceridemia risk: Bile acid sequestrants can increase triglycerides; avoid if TG ≥300 mg/dL 6. Monitor triglycerides closely and discontinue if pancreatitis symptoms develop 1
- GI obstruction: Not recommended in patients with gastroparesis or other GI motility disorders 1
- Drug interactions: Administer other medications at least 4 hours before colesevelam to prevent absorption interference 1
- Fat-soluble vitamin deficiencies: May decrease absorption of vitamins A, D, E, and K; supplement at least 4 hours before colesevelam 1
Practical Considerations
Dosing: 3.75 g daily (6 tablets once daily or 3 tablets twice daily with meals, or oral suspension) 2
For your specific patient: The elevated liver enzymes and impaired renal function do not represent absolute contraindications, as colesevelam is non-systemic. However, you must first verify the triglyceride level—if >500 mg/dL, colesevelam is absolutely contraindicated 1. If TG is 300-500 mg/dL, use extreme caution with close monitoring. The hyperchloremia and albuminuria are not relevant to colesevelam prescribing decisions.